H1 Is First to Arm Biopharma Companies with Live Data Insights to Help Fight Diseases
H1 has built a technology infrastructure grounded in machine intelligence that enables it to quickly find and surface relevant data from any public clinical and scholarly database anywhere in the world. The company layers in curated data harvested from hundreds of thousands of website profiles and conference presentations.
The result: what used to take a healthcare organization a month to find and analyze (if they could find it at all), now takes H1 just hours.
Ariel Katz, co-founder of H1, came to Shore Group when the company acquired his startup Labspot in 2016. He had a vision for a data company focused solely on healthcare, and Shore Group encouraged him to start H1 in late 2017. Incubated at Shore Group, over the past year, H1 grew swiftly, signing well over seven figures in revenue across some of the largest biopharma companies.
“H1 has been very successful in developing technology that surfaces hard-to-find healthcare data, and arms clients with that data so they can make better and faster data-driven decisions along their development pipeline,” said Ian Sax, CEO of Shore Group. “Ariel has opened our eyes to the big opportunities in healthcare data and we are excited to continue to invest in H1.”
Katz said, “With expertise in data collection for some of the largest global financial institutions, Shore Group was the ideal incubation spot for H1, as we established ourselves in the healthcare data space. Now that we are on solid footing, with a clear path to growth, we’re excited to operate independently, with Shore Group’s backing as an investor.”